Drug Profile
Research programme: metabolic disease therapy - KineMed/Pfizer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator KineMed; Pfizer
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in USA
- 04 Jun 2014 KineMed and Pfizer renew their collaboration in metabolic diseases, including type 2 diabetes mellitus
- 31 Jan 2012 Early research in Metabolic disorders in USA (unspecified route)